Open Access

The mediation of interleukin‑17 and chemokine ligand 2 in pelvic pain of experimental autoimmune prostatitis

  • Authors:
    • Xiaodong Liu
    • Shicheng Fan
    • Mingxing Zheng
    • Jianheng Chen
    • Jianhua Zhang
    • Hao Li
  • View Affiliations

  • Published online on: May 11, 2017     https://doi.org/10.3892/etm.2017.4448
  • Pages: 51-58
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to determine the expression and mediation of interleukin‑17 (IL‑17) and chemokine ligand 2 (CCL2) in a rat model with experimental autoimmune prostatitis (EAP). A total of 44 Sprague Dawley (SD) rats were used in the present study. Of these, a total of 20 two‑month‑old SD rats were randomly divided into a normal control (n=10) and a model group (EAP group, n=10). The remaining 24 two‑month old SD rats were treated in the same way as EAP rats and subsequently randomly divided into a tacrolimus group (n=8), a celecoxib group (n=8) and a normal saline (NS) control group (n=8). Rats in the EAP and normal control groups underwent the Von Frey filaments behavioral test; rats in the tacrolimus, celecoxib and normal saline groups received a pain test following intervention treatment. Prostate tissues of SD rats in each group were harvested for reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis to observe the expression of IL‑17 and CCL2. In the pain‑reaction test, the occurrence of abnormal pain in the EAP group was significantly higher compared with the control group (P<0.001). The celecoxib group experienced a significant decrease in pain at day 10 compared with the NS group (P<0.01), while the decrease in pain experienced by the tacrolimus group was only significant at day 30 (P<0.001) and the pain experienced by the NS group decreased slightly over this same period. Results of RT‑qPCR and western blot analysis indicated that, compared with the control group, the expression of IL‑17 and CCL2 in the prostate tissue of EAP rats was significantly upregulated 50 days following modeling (P<0.05). On day 30 following intervention, the expression of IL‑17 and CCL2 in the prostate of rats in the tacrolimus and celecoxib groups was significantly downregulated compared with the NS group (P<0.05). Therefore, the results of the current study demonstrate that IL‑17 and CCL2 serve a vital role in the morbidity of the experimental autoimmune prostatitis and may also have a mediation effect on pelvic pain associated with chronic prostatitis.

References

1 

Collins MM, Stafford RS, O'Leary MP and Barry MJ: Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: Results of a national survey of physician visits. Urology. 53:921–925. 1999. View Article : Google Scholar : PubMed/NCBI

2 

Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG and Jacobsen SJ: Prevalence of a physician-assigned diagnosis of prostatitis: The Olmsted County study of urinary symptoms and health status Among Men. Urology. 51:578–584. 1998. View Article : Google Scholar : PubMed/NCBI

3 

Tan JK, Png DJ, Liew LC, Li MK and Wong ML: Prevalence of prostatitis-like symptoms in Singapore: A population-based study. Singap Med J. 43:189–193. 2002.

4 

Ku JH, Kim ME, Lee NK and Park YH: Influence of environmental factors on chronic prostatitis-like symptoms in young men: Results of a community-based survey. Urology. 58:853–858. 2001. View Article : Google Scholar : PubMed/NCBI

5 

Krieger JN, Riley DE, Cheah PY, Liong ML and Yuen KH: Epidemiology of prostatitis: New evidence for a world-wide problem. World J Urol. 21:70–74. 2003. View Article : Google Scholar : PubMed/NCBI

6 

Guo YH and Li HJ: ProstatitisPeople's Military Medical Press; Beijing; pp. 682007

7 

Krieger JN, Nyberg LJ Jr and Nickel JC: NIH Consensus definition and classification of prostatitis. JAMA. 282:236–237. 1999. View Article : Google Scholar : PubMed/NCBI

8 

Quick ML, Wong L, Mukherjee S, Done JD, Schaeffer AJ and Thumbikat P: Th1-Th17 cells contribute to the development of uropathogenic Escherichia coli-induced chronic pelvic pain. PLoS One. 8:e609872013. View Article : Google Scholar : PubMed/NCBI

9 

Zhang K: Guide for the Diagnosis and Treatment of Prostatitis. People's Medical Publishing House; Beijing: 2009

10 

Rowe E, Smith C, Laverick L, Elkabir J, Witherow RO and Patel A: A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup. J Urol. 173:2044–2047. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Seethalakshmi L, Bala RS, Malhotra RK, Austin-Ritchie T, Miller-Graziano C, Menon M and Luber-Narod J: 17 beta-estradiol induced prostatitis in the rat is an autoimmune disease. J Urol. 156:1838–1842. 1996. View Article : Google Scholar : PubMed/NCBI

12 

Mahal BA, Cohen JM, Allsop SA, Moore JB, Bhai SF, Inverso G and Dimitrakoff JD: The role of phenotyping in chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 12:297–303. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Wagenlehner FM, Pilatz A, Bschleipfer T, Diemer T, Linn T, Meinhardt A, Schagdarsurengin U, Dansranjavin T, Schuppe HC and Weidner W: Bacterial prostatitis. World J Urol. 31:711–716. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, et al: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 421:744–748. 2003. View Article : Google Scholar : PubMed/NCBI

15 

Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q and Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI

16 

Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA and Cua DJ: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 201:233–240. 2005. View Article : Google Scholar : PubMed/NCBI

17 

Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA and van den Berg WB: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50:650–659. 2004. View Article : Google Scholar : PubMed/NCBI

18 

Miller LJ, Fischer KA, Goralnick SJ, Litt M, Burleson JA, Albertsen P and Kreutzer DL: Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome. Urology. 59:603–608. 2002. View Article : Google Scholar : PubMed/NCBI

19 

Arms L, Girard BM, Malley SE and Vizzard MA: Expression and function of CCL2/CCR2 in rat micturition reflexes and somatic sensitivity with urinary bladder inflammation. Am J Physiol Renal Physiol. 305:F111–F122. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Donadio AC and Depiante-Depaoli M: Inflammatory cells and MHC class II antigens expression in prostate during time-course experimental autoimmune prostatitis development. Clin Immunol Immunopathol. 85:158–165. 1997. View Article : Google Scholar : PubMed/NCBI

21 

Schmidt R, Schmelz M, Ringkamp M, Handwerker HO and Torebjörk HE: Innervation territories of mechanically activated C nociceptor units in human skin. J Neurophysiol. 78:2641–2648. 1997.PubMed/NCBI

22 

Rudick CN, Schaeffer AJ and Thumbikat P: Experimental autoimmune prostatitis induces chronic pelvic pain. Am J Physiol Regul Integr Comp Physiol. 294:R1268–R1275. 2008. View Article : Google Scholar : PubMed/NCBI

23 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

24 

Fen ZG, Yan WJ, Zhang J and Xu Y: Effects of Calcium Concentration on the Soluble Gq Protein α Subunit in the Photoreceptor Cell of Macrobrachium rosenbergi on Light Adaptation and Dark Adaptation. Zoolog Res. 24:373–376. 2003.

25 

Depiante-Depaoli M and Pacheco-Rupil B: Experimental autoimmunity to rat male accessory glands (MAG): Circulating antibodies, immunoglobulins bound to target glands, and immunoglobulins-secreting cells. Am J Reprod Immunol Microbiol. 7:32–38. 1985. View Article : Google Scholar : PubMed/NCBI

26 

Schaeffer AJ: Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med. 355:1690–1698. 2006. View Article : Google Scholar : PubMed/NCBI

27 

John H, Barghorn A, Funke G, Sulser T, Hailemariam S, Hauri D and Joller-Jemelka H: Noninflammatory chronic pelvic pain syndrome: Immunological study in blood, ejaculate and prostate tissue. Eur Urol. 39:72–78. 2001. View Article : Google Scholar : PubMed/NCBI

28 

Pontari MA: Chronic prostatitis/chronic pelvic pain syndrome in elderly men: Toward better understanding and treatment. Drugs Aging. 20:1111–1125. 2003. View Article : Google Scholar : PubMed/NCBI

29 

Orhan I, Onur R, Ilhan N and Ardiçoglu A: Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome. Int J Urol. 8:495–499. 2001. View Article : Google Scholar : PubMed/NCBI

30 

Alexander RB, Ponniah S, Hasday J and Hebel JR: Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology. 52:744–749. 1998. View Article : Google Scholar : PubMed/NCBI

31 

Zhang ZY and Schluesener HJ: HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis. Prostate. 72:90–99. 2012. View Article : Google Scholar : PubMed/NCBI

32 

Shahed AR and Shoskes DA: Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. J Urol. 166:1738–1741. 2001. View Article : Google Scholar : PubMed/NCBI

33 

Taguchi O and Nishizuka Y: Self tolerance and localized autoimmunity. Mouse models of autoimmune disease that suggest tissue-specific suppressor T cells are involved in self tolerance. J Exp Med. 165:146–156. 1987. View Article : Google Scholar : PubMed/NCBI

34 

Motrich RD, Maccioni M, Riera CM and Rivero VE: Autoimmune prostatitis: State of the art. Scand J Innunol. 66:217–227. 2007. View Article : Google Scholar

35 

Pacheco-Rupil B, Depiante-Depaoli M and Casadio B: Experimental autoimmune damage to rat male accessory glands. II. T cell requirement in adoptive transfer of specific tissue damage. Am J Reprod Immunol. 5:15–19. 1984. View Article : Google Scholar : PubMed/NCBI

36 

Ishigooka M, Zermann DH, Doggweiler R and Schmidt RA: Similarity of distributions of spinal c-fos and plasma extravasation after acute chemical irritation of the bladder and the prostate. J Urol. 164:1751–1756. 2000. View Article : Google Scholar : PubMed/NCBI

37 

Quick ML, Wong L, Mukherjee S, Done JD, Schaeffer AJ and Thumbikat P: Th 1-Th 17 cells contribute to the development of uropathogenic Escherichia coli-induced chronic pelvic pain. PLoS One. 8:e609872013. View Article : Google Scholar : PubMed/NCBI

38 

Day YJ, Liou JT, Lee CM, Lin YC, Mao CC, Chou AH, Liao CC and Lee HC: Lack of interleukin-17 leads to a modulated micro-environment and amelioration of mechanical hypersensitivity after peripheral nerve injury in mice. Pain. 155:1293–1302. 2014. View Article : Google Scholar : PubMed/NCBI

39 

Murphy SF, Schaeffer AJ, Done J, Wong L, Bell-Cohn A, Roman K, Cashy J, Ohlhausen M and Thumbikat P: IL17 Mediates Pelvic Pain in Experimental Autoimmune Prostatitis (EAP). PLoS One. 10:e01256232015. View Article : Google Scholar : PubMed/NCBI

40 

Quick ML, Mukherjee S, Rudick CN, Done JD, Schaeffer AJ and Thumbikat P: CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis. Am J Physiol Regul Integr Comp Physiol. 303:R580–R589. 2012. View Article : Google Scholar : PubMed/NCBI

41 

Rivero VE, Cailleau C, Depiante-Depaoli M, Riera CM and Carnaud C: Non-obese diabetic (NOD) mice are genetically susceptible to experimental autoimmune prostatitis (EAP). J Autoimmun. 11:603–610. 1998. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2017
Volume 14 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, X., Fan, S., Zheng, M., Chen, J., Zhang, J., & Li, H. (2017). The mediation of interleukin‑17 and chemokine ligand 2 in pelvic pain of experimental autoimmune prostatitis. Experimental and Therapeutic Medicine, 14, 51-58. https://doi.org/10.3892/etm.2017.4448
MLA
Liu, X., Fan, S., Zheng, M., Chen, J., Zhang, J., Li, H."The mediation of interleukin‑17 and chemokine ligand 2 in pelvic pain of experimental autoimmune prostatitis". Experimental and Therapeutic Medicine 14.1 (2017): 51-58.
Chicago
Liu, X., Fan, S., Zheng, M., Chen, J., Zhang, J., Li, H."The mediation of interleukin‑17 and chemokine ligand 2 in pelvic pain of experimental autoimmune prostatitis". Experimental and Therapeutic Medicine 14, no. 1 (2017): 51-58. https://doi.org/10.3892/etm.2017.4448